Abstract

A REVIEW ON TREATMENT OF RENAL ANEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND HEMODIALYSIS

Shalini Bahuguna* and Devesh Joshi

Abstract

Anemia is one of the most common and morbid complications of chronic kidney disease, causing unpleasant symptoms and reducing the quality of life. It is a very common complication of CKD and result in the interference of erythropoietin production. The rate of release of erythropoietin from the kidney is greatly enhanced by various forms of hypoxia, anemia, and carbon monoxide poisoning. Anemia affects 60- 80% of patients with renal impairment and is common in both pre -dialysis and on dialysis leading to reduced quality of life and additional risk factor for early death. Treatment with erythropoietin with intravenous therapy in patients receiving haemodialysis, showed that there was a dose dependent rate of response to the hormone. The treatment with recombinant Epo has resulted in a remarkable improvement in global well being and quality of life.

Keywords: Anemia, Hypoxia, Chronic Kidney Disease, Erythropoietin, Hemodialysis, Quality of Life.